1.	Stereotactic Body Radiotherapy for Prostate Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-022, NCT01352598
2.	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Phase: Phase IV Type: Treatment Status: Active Age: 40 and over Sponsor: Other Protocol IDs: Thin-1, NCT01379742
3.	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IRB# 11-002288, NCT01365143
4.	Firmagon (Degarelix) Intermittent Therapy Phase: Phase IV Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: CURC - FIT-0002, NCT01512472
5.	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 4-2007-0344, NCT01547416
6.	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Phase: Phase IV Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: R12-3104L, NCT01581749
7.	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZ_L_06003, U1111-1123-9025, NCT01649635
8.	GP Extended Action Triptorelin Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A-97-52014-181, 2011-004213-16, NCT01673984
9.	Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100856, 212082PCR4003, NCT01692483
10.	A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A-38-52014-194, NCT01753297
11.	Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: KEK-ZH-NR:2010-0004/0, NCT01770340
12.	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230B2412, NCT01794793
13.	STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000455008, MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
14.	Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 40 to 75 Sponsor: NCI Protocol IDs: UIC-2006-0706, 2006-0706, NCT00765479
15.	External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: GU004-11, NCT01603420
16.	Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
17.	Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 19 to 90 Sponsor: Other Protocol IDs: CLIN-007-12S, Pro00019745, NCT01759771
18.	Hormone Therapy in Treating Men With Stage IV Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Adult Sponsor: NCI, Other Protocol IDs: CDR0000064184, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, PR8, NCT00002651
19.	Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000365458, FCCC-03028, NCT00084552
20.	Androgen Deprivation Therapy in Treating Patients With Prostate Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: PMCC-VCOG-PR-0103, PMCC-TROG-0306, NCT00110162
21.	Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: Other Protocol IDs: CDR0000416088, FRE-FNCLCC-GETUG-14/0207, EU-20503, NCT00104741
22.	Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 30 and over Sponsor: Other Protocol IDs: 05-043, NCT00116142
23.	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Phase: Phase III Type: Treatment Status: Active Age: 20 to 79 Sponsor: Other Protocol IDs: JCOG0401, C000000026, NCT00138008
24.	Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PCS III, DC-990-0049, NCT00223145
25.	Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PCS IV, DC-990-0056, NCT00223171